(Q41692347)

English

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

scientific article published on June 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

object named as

Rodryg Ramlau

7

0 references

György Losonczy

10

object named as

György Losonczy

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Aleksandra Szczesna

4

object named as

Aleksandra Szczesna

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

author name string

Nick Thatcher

1

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Fred R Hirsch

2

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Alexander V Luft

3

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Tudor E Ciuleanu

5

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Mircea Dediu

6

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Rinat K Galiulin

8

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Beatrix Bálint

9

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Andrzej Kazarnowicz

11

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Keunchil Park

12

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Christian Schumann

13

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Martin Reck

14

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Henrik Depenbrock

15

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Shivani Nanda

16

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Anamarija Kruljac-Letunic

17

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Raffael Kurek

18

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Luis Paz-Ares

19

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Mark A Socinski

20

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

SQUIRE Investigators

21

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

publication date

1 June 2015

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

763-774

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-small-cell lung cancers: a heterogeneous set of diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Squamous cell lung cancer: from tumor genomics to cancer therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/In

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Management and future directions in non-small cell lung cancer with known activating mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular Markers with Predictive and Prognostic Relevance in Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Considerations for second-line therapy of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential ErbB receptor expression and intracellular signaling activity in lung adenocarcinomas and squamous cell carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

EuroQol: health-related quality of life measurement. Valuations of health states by the general public in Norway

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A sharper Bonferroni procedure for multiple tests of significance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Systematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900021-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)00021-2

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41692347&oldid=1926010122"